$4.08
3.55% yesterday
Nasdaq, Jan 06, 10:00 pm CET
ISIN
US75955J2042
Symbol
RLMD

Relmada Therapeutics Inc Stock price

$4.08
-0.09 2.16% 1M
+3.47 568.63% 6M
-0.75 15.53% YTD
+3.64 827.27% 1Y
+0.79 24.01% 3Y
-29.35 87.80% 5Y
-6.72 62.22% 10Y
-55.92 93.20% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
-0.15 3.55%
ISIN
US75955J2042
Symbol
RLMD
Industry

Key metrics

Basic
Market capitalization
$299.2m
Enterprise Value
$285.3m
Net debt
positive
Cash
$13.9m
Shares outstanding
33.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
31.6
Financial Health
Equity Ratio
77.5%
Return on Equity
-225.2%
ROCE
-596.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-105.6m
EBIT
$-57.8m | $-50.2m
Net Income
$-56.2m | $-41.6m
Free Cash Flow
$-40.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
37.0% | 40.2%
Net Income
35.4% | 47.9%
Free Cash Flow
25.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
1.3%
Employees
17
Rev per Employee
$0.0
Show more

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Relmada Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Relmada Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
33% 33%
-
- Research and Development Expense 30 30
40% 40%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -58 -58
37% 37%
-
Net Profit -56 -56
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, repre...
Neutral
Seeking Alpha
about 2 months ago
Relmada Therapeutics, Inc. ( RLMD ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Sergio Traversa - CEO & Director Raj Pruthi - Chief Medical Officer of Urology Maged Shenouda - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Uy Ear - Mizuho Securities USA LLC, Research Division Presentation Operator Good afternoon, and welco...
Neutral
GlobeNewsWire
about 2 months ago
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Sergio Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today